COVID-19 vaccines: The status and perspectives in delivery points of view

JY Chung, MN Thone, YJ Kwon - Advanced drug delivery reviews, 2021 - Elsevier
Due to the high prevalence and long incubation periods often without symptoms, the severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals …

[HTML][HTML] Immune response in COVID-19: A review

MA Chowdhury, N Hossain, MA Kashem… - Journal of infection and …, 2020 - Elsevier
The immune system protects us from viruses and diseases. It produces an antibody to kill
pathogen. This review shows a brief picture about the immune system to protect us from …

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

A Agarwal, A Mukherjee, G Kumar, P Chatterjee… - bmj, 2020 - bmj.com
Objective To investigate the effectiveness of using convalescent plasma to treat moderate
coronavirus disease 2019 (covid-19) in adults in India. Design Open label, parallel arm …

Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study

STH Liu, HM Lin, I Baine, A Wajnberg, JP Gumprecht… - Nature medicine, 2020 - nature.com
Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective …

Potential therapeutic options for COVID-19: an update on current evidence

Z Niknam, A Jafari, A Golchin, F Danesh Pouya… - European journal of …, 2022 - Springer
Abstract SARS-CoV-2, a novel coronavirus, is the agent responsible for the COVID-19
pandemic and is a major public health concern nowadays. The rapid and global spread of …

COVID‐19–associated Guillain‐Barré syndrome: The early pandemic experience

JB Caress, RJ Castoro, Z Simmons, SN Scelsa… - Muscle & …, 2020 - Wiley Online Library
Guillain‐Barré syndrome (GBS) is an inflammatory polyradiculoneuropathy associated with
numerous viral infections. Recently, there have been many case reports describing the …

Pharmaco-immunomodulatory therapy in COVID-19

JG Rizk, K Kalantar-Zadeh, MR Mehra, CJ Lavie… - Drugs, 2020 - Springer
The severe acute respiratory syndrome coronavirus 2 associated coronavirus disease 2019
(COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory …

Role of inflammatory cytokines in COVID-19 patients: A review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to …

AA Rabaan, SH Al-Ahmed, J Muhammad, A Khan… - Vaccines, 2021 - mdpi.com
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), is a severe pandemic of the current century. The vicious …

Wuhan to world: the COVID-19 pandemic

A Kumar, R Singh, J Kaur, S Pandey… - Frontiers in cellular …, 2021 - frontiersin.org
COVID-19 is a Severe Acute Respiratory Syndrome (SARS), caused by SARS-CoV-2, a
novel virus which belongs to the family Coronaviridae. It was first reported in December …

Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19

MA Thompson, JP Henderson, PK Shah… - JAMA …, 2021 - jamanetwork.com
Importance COVID-19 is a life-threatening illness for many patients. Prior studies have
established hematologic cancers as a risk factor associated with particularly poor outcomes …